Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

Rhea-AI Summary

Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a fireside chat at the Guggenheim 4th Annual Immunology & Neurology Day on November 15, 2022, at 10:10 a.m. ET in New York City. A live webcast will be accessible on their website, and a replay will be available for 30 days post-event. The company is focused on developing therapies for CNS disorders, with ongoing programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia, enhancing treatment access through its collaboration with the University of Pennsylvania.

PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology & Neurology Day on Tuesday, November 15, 2022 at 10:10 a.m. ET in New York, NY.

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Passage Bio Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
MikeBeyer@sambrown.com

FAQ

What event will Passage Bio's CEO participate in on November 15, 2022?

William Chou, CEO of Passage Bio, will participate in a fireside chat at the Guggenheim 4th Annual Immunology & Neurology Day.

What is the focus of Passage Bio's clinical programs?

Passage Bio focuses on developing therapies for central nervous system disorders, including GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.

How can I watch the Guggenheim event featuring Passage Bio?

A live webcast of the event will be available on Passage Bio's website, along with a replay for 30 days.

What collaborations does Passage Bio have for its research?

Passage Bio has established a strategic collaboration with the University of Pennsylvania’s Gene Therapy Program for its discovery and preclinical work.

What is the stock symbol for Passage Bio?

The stock symbol for Passage Bio is NASDAQ: PASG.